A Phase 3 interventional study of Feladilimab and Pembrolizumab in Neoplasms, Head and Neck, sponsored by GlaxoSmithKline. Terminated at 71 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada — 30 open to participants now, 57 under way, 13 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Canada.
Among the 164 studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada, this one is the 80th largest by enrollment of the 149 interventional ones that give a count, is one of 16 that started in 2020, is one of 33 in phase 3, and was the 106th registered.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →30 of the 164 studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada are open now. Recruiting first, the newest first:
Corbus Pharmaceuticals Inc. · Sites in Canada, United States, Austria and 11 more countries
Ages 18+
University of British Columbia · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
EMD Serono Research & Development Institute, Inc. · Sites in Canada, United States, Japan and 1 more country
Ages 18+
AbbVie · Sites in Canada, United States, Israel and 1 more country
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 62 · Phase 2 61 · Phase 3 39 · Phase 4 1
First in 1995; this study’s year is marked. 16 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 129 across the 149 interventional studies, 35 across the 9 observational. Of the 100 that completed or were terminated, 36 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 164 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 9 studies filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
16 of the studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT06147037AstraZenecaA Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | 2026-12-31 |
| NCT06578871London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sSurgery and Reducing Ionizing Radiation of the Unknown Primary | 2026-12-31 |
| NCT05941507LigaChem Biosciences, Inc.A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | 2027-01 |
Add all 16 to your calendar (.ics) → With an account.
Among the 164 studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate if the addition of GSK3359609 to pembrolizumab in combination with 5FU-platinum based chemotherapy improves the efficacy of the pembrolizumab combination with 5FU-platinum based chemotherapy in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). This randomized, double-blinded, Phase II/III study will compare the combination of GSK3359609 with pembrolizumab and 5FU-platinum chemotherapy to placebo in combination with pembrolizumab and 5FU-platinum chemotherapy in participants with recurrent or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx or larynx.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
This study's enrollment of 117 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Browse Squamous Cell Carcinoma of Head and Neck studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Squamous Cell Carcinoma of Head and Neck, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Feladilimab · Drug: Pembrolizumab · Drug: Platinum based chemotherapy · Drug: Fluorouracil (5FU)
Drug: Pembrolizumab · Drug: Placebo · Drug: Platinum based chemotherapy · Drug: Fluorouracil (5FU)
Humanized anti-inducible T cell co-stimulatory receptor (ICOS) immunoglobulin G4 (IgG4) monoclonal antibody (mAb)
Humanized anti- programmed cell death receptor1 (anti-PD-1) IgG4 mAb
Sterile normal saline
Cisplatin/carboplatin
5-fluorouracil
Overall Survival (OS) in mITT Population
OS was defined as the time from the date of randomization to the date of death due to any cause. Kaplan-Meier estimate for the median OS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.
Time frame: Up to approximately 7 months
OS in Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 Population
OS was defined as the time from the date of randomization until the date of death due to any cause. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median OS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.
Time frame: Up to approximately 7 months
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 in mITT Population
PFS per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 was defined as the time from the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.
Time frame: Up to approximately 7 months
PFS Per RECIST v1.1 in the PD-L1 CPS ≥1 Population
PFS per RECIST v1.1 was defined as the time from the date of randomization until the date of disease progression or death due to any cause, whichever occurs first. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.
Time frame: Up to approximately 7 months
Milestone OS Rate at 12, 24 and 36 Months in mITT Population
Milestone OS rate at 12, 24, and 36 months was not evaluated.
Time frame: Months 12, 24 and 36
Milestone OS Rate at 12, 24 and 36 Months in PD-L1 CPS ≥1 Population
Milestone OS rate at 12, 24, and 36 months was not evaluated. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
Time frame: Months 12, 24 and 36
Overall Response Rate (ORR) Per RECIST v1.1 in mITT Population
ORR per RECIST v1.1 was defined as the proportion of the participants who have a complete response (CR) or partial response (PR) as the best overall response per RECIST v1.1 based upon investigator assessment. As a randomized double-blind study in which primary endpoints are OS and PFS, the confirmation of CR and PR was not required. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted.
Time frame: Up to approximately 7 months
ORR Per RECIST v1.1 in PD-L1 CPS ≥1 Population
ORR per RECIST v1.1 was defined as the proportion of the participants who have a complete response (CR) or partial response (PR) as the best overall response per RECIST v1.1 based upon investigator assessment. As a randomized double-blind study in which primary endpoints are OS and PFS, the confirmation of CR and PR was not required. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
Time frame: Up to approximately 7 months
Disease Control Rate (DCR) Per RECIST v1.1 in mITT Population
DCR per RECIST v1.1 based upon investigator assessment, was defined as the percentage of participants with a best overall response of CR or PR at any time plus stable disease (SD) meeting the minimum time of 15 weeks. A status of SD≥15 weeks will be assigned if the follow-up disease assessment has met the SD criteria at least once after the date of randomization at a minimum of 14 weeks (98 days) considering a one-week visit window. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted.
Time frame: Up to approximately 7 months
DCR Per RECIST v1.1 in PD-L1 CPS ≥1 Population
DCR per RECIST v1.1 based upon investigator assessment, was defined as the percentage of participants with a best overall response of CR or PR at any time plus stable disease (SD) meeting the minimum time of 15 weeks. A status of SD≥15 weeks will be assigned if the follow-up disease assessment has met the SD criteria at least once after the date of randomization at a minimum of 14 weeks (98 days) considering a one-week visit window. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
Time frame: Up to approximately 7 months
Duration of Response (DoR) Per RECIST v1.1 in mITT Population
DoR per RECIST v1.1 is defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. Kaplan-Meier estimate for the median DoR is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.
Time frame: Up to approximately 7 months
DoR Per RECIST v1.1 in PD-L1 CPS ≥1 Population
DoR per RECIST v1.1 is defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. Kaplan-Meier estimate for the median DoR is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
Time frame: Up to approximately 7 months
Number of Participants With Adverse Events (AEs) in Safety Population
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention
Time frame: Up to approximately 37.2 months
Number of Participants With Serious Adverse Events (SAEs) in Safety Population
SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and other situations according to medical or scientific judgement.
Time frame: Up to approximately 37.2 months
Number of Participants With Adverse Events of Special Interest (AESI) in Safety Population
AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs).
Time frame: Up to approximately 37.2 months
Number of Participants With AEs in Programmed Death Ligand-1 (PD-L1) Combined Positive Score (CPS ≥1) Population
Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
Time frame: Up to approximately 37.2 months
Number of Participants With SAEs in PD-L1 CPS ≥1 Population
SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and other situations according to medical or scientific judgement. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
Time frame: Up to approximately 37.2 months
Number of Participants With AESIs in PD-L1 CPS ≥1 Population
AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
Time frame: Up to approximately 37.2 months
Severity of AEs in Safety Population
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity for each AE was reported during the study and assigned a grade according to the NCI-CTCAE v5.0. from Grade 1 through Grade 5. Grade 1= mild toxicity; Grade 2 = moderate toxicity; Grade 3 = severe toxicity; Grade 4 = life-threatening or disabling toxicity, Grade 5 = death related to toxicity.
Time frame: Up to approximately 37.2 months
Severity of SAEs in Safety Population
A SAE was defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. Severity for each SAE was reported during the study and assigned a grade according to the NCI-CTCAE v5.0. from Grade 1 through Grade 5. Grade 1= mild toxicity; Grade 2 = moderate toxicity; Grade 3 = severe toxicity; Grade 4 = life-threatening or disabling toxicity, Grade 5 = death related to toxicity. Data of participants experiencing SAEs of Grade \>= 3 has been presented.
Time frame: Up to approximately 37.2 months
Severity of AESIs in Safety Population
AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). Severity of each AESI was reported during the study and was assigned a grade according to the NCI-CTCAE. AESIs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE. Data of participants experiencing AESIs of Grade \>= 3 have been presented.
Time frame: Up to approximately 37.2 months
Severity of AEs in PD-L1 CPS ≥1 Population
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity for each AE was reported during the study and assigned a grade according to the NCI-CTCAE v5.0. from Grade 1 through Grade 5. Grade 1= mild toxicity; Grade 2 = moderate toxicity; Grade 3 = severe toxicity; Grade 4 = life-threatening or disabling toxicity, Grade 5 = death related to toxicity. Data of participants experiencing AEs of Grade \>= 3 have been presented. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
Time frame: Up to approximately 37.2 months
Severity of SAEs in PD-L1 CPS ≥1 Population
A SAE was defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. Severity for each SAE was reported during the study and assigned a grade according to the NCI-CTCAE v5.0. from Grade 1 through Grade 5. Grade 1= mild toxicity; Grade 2 = moderate toxicity; Grade 3 = severe toxicity; Grade 4 = life-threatening or disabling toxicity, Grade 5 = death related to toxicity. Data of participants that experienced SAEs of Grade \>= 3 have been presented. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
Time frame: Up to approximately 37.2 months
Severity of AESI in PD-L1 CPS ≥1 Population
AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). Severity of each AESI was reported during the study and was assigned a grade according to the NCI-CTCAE. AESIs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE. Data of participants that experienced AESIs of Grade \>= 3 have been presented.
Time frame: Up to approximately 37.2 months
Number of Participants With Dose Modifications in Safety Population
Number of participants with dose modifications (including dose interruptions, dose delays, dose reductions and treatment discontinuations) were reported by each interventional component.
Time frame: Up to approximately 7 months
Number of Participants With Dose Modifications in PD-L1 CPS ≥1 Population
Number of participants with dose modifications (including dose interruptions, dose delays, dose reductions and treatment discontinuations) were reported by each interventional component. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
Time frame: Up to approximately 7 months
Time to Deterioration (TTD) in Pain in mITT Population
TTD in pain is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the European Organization for Research and Treatment of Cancer Item Library(EORTC IL51) Questionnaire pain domain, i.e. an increase from baseline of at least 8.33 observed at all subsequent non-missing visits. The EORTC Quality of Life Questionnaire 35-Item Head and Neck Module (QLQ-H\&N35) is a head and neck specific module with multi-item scales. The mouth pain, swallowing, speech problems, opening mouth, coughing, feeding tube, and trouble with social eating domains were administered and referred to as the EORTC IL51. The questionnaire scores for each scale and single-item measure are averaged and transformed linearly to present a score ranging from 0-100. A high score represents a high/healthy level of functioning. Kaplan-Meier estimate for the median TTD is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.
Time frame: Up to approximately 7 months
TTD in Pain in PD-L1 CPS ≥1 Population
TTD in pain is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the EORTC IL51 pain domain, i.e. an increase from baseline of at least 8.33 observed at all subsequent non-missing visits. The EORTC QLQ-H\&N35 is a head and neck specific module with multi-item scales. The mouth pain, swallowing, speech problems, opening mouth, coughing, feeding tube, and trouble with social eating domains were administered and referred to as the EORTC IL51. The questionnaire scores for each scale and single-item measure are averaged and transformed linearly to present a score ranging from 0-100. A high score represents a high/healthy level of functioning. Kaplan-Meier estimate for the median TTD is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells to the total number of viable tumor cells.
Time frame: Up to approximately 7 months
TTD in Physical Function in mITT Population
TTD in physical function (PF) is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the PF T-score, i.e. a decrease from baseline of at least 2.4 observed at all subsequent non-missing visits, as measured by the Patient-Reported Outcomes Measurement Information System - Physical Function (PROMIS PF 8c).The PROMIS PF 8c is an 8-item fixed length short form derived from the PROMIS Physical Function item bank. It includes a 5-point scale with three sets of response options. Scores on the PROMIS PF 8c are reported on a T score metric (mean = 50 and SD = 10), with higher scores reflecting better physical functioning.
Time frame: Up to approximately 7 months
TTD in Physical Function in PD-L1 CPS ≥1 Population
TTD in PF is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the PF T-score, i.e. a decrease from baseline of at least 2.4 observed at all subsequent non-missing visits, as measured by the PROMIS PF 8c.The PROMIS PF 8c is an 8-item fixed length short form derived from the PROMIS Physical Function item bank. It includes a 5-point scale with three sets of response options. Scores on the PROMIS PF 8c are reported on a T score metric (mean = 50 and SD = 10), with higher scores reflecting better physical functioning. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells
Time frame: Up to approximately 7 months
Recruitment in the study stopped following the review of unblinded interim safety and efficacy data by IDMC, after a pre-specified futility analysis of the 209229(NCT04128696) trial. A Dear investigator letter (DIL) was issued to stop screening \& randomization of more participants in both studies. Participants discontinued feladilimab/placebo, but treatment with pembrolizumab plus fluorouracil (5FU) platinum chemotherapy continued until disease progression, death or unacceptable toxicity.
| Milestone | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Started | 57 | 60 |
| Modified intent-to-treat (mitt) population | 52 | 55 |
| Safety population | 51 | 65 |
| Completed | 37 | 35 |
| Not completed | 20 | 25 |
| Withdrew: Physician decision | 5 | 6 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Study terminated by sponsor | 14 | 16 |
OS was defined as the time from the date of randomization to the date of death due to any cause. Kaplan-Meier estimate for the median OS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.
| Months | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Overall Survival (OS) in mITT Population | NA (5.1 to NA) | NA (4.1 to NA) |
OS was defined as the time from the date of randomization until the date of death due to any cause. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median OS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.
| Months | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| OS in Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 Population | NA (5.1 to NA) | NA (4.1 to NA) |
PFS per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 was defined as the time from the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.
| Months | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 in mITT Population | 5.5 (3.7 to 5.5) | 4.7 (4.7 to 5.6) |
PFS per RECIST v1.1 was defined as the time from the date of randomization until the date of disease progression or death due to any cause, whichever occurs first. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.
| Months | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| PFS Per RECIST v1.1 in the PD-L1 CPS ≥1 Population | 5.5 (3.7 to 5.5) | 4.7 (4.7 to 6.1) |
Milestone OS rate at 12, 24, and 36 months was not evaluated.
No measurements were reported for this outcome.
Milestone OS rate at 12, 24, and 36 months was not evaluated. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
No measurements were reported for this outcome.
ORR per RECIST v1.1 was defined as the proportion of the participants who have a complete response (CR) or partial response (PR) as the best overall response per RECIST v1.1 based upon investigator assessment. As a randomized double-blind study in which primary endpoints are OS and PFS, the confirmation of CR and PR was not required. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted.
| Percentage of participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Overall Response Rate (ORR) Per RECIST v1.1 in mITT Population | 19.2 (9.6 to 32.5) | 23.6 (13.2 to 37.0) |
ORR per RECIST v1.1 was defined as the proportion of the participants who have a complete response (CR) or partial response (PR) as the best overall response per RECIST v1.1 based upon investigator assessment. As a randomized double-blind study in which primary endpoints are OS and PFS, the confirmation of CR and PR was not required. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
| Percentage of participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| ORR Per RECIST v1.1 in PD-L1 CPS ≥1 Population | 18.4 (8.8 to 32.0) | 23.1 (12.5 to 36.8) |
DCR per RECIST v1.1 based upon investigator assessment, was defined as the percentage of participants with a best overall response of CR or PR at any time plus stable disease (SD) meeting the minimum time of 15 weeks. A status of SD≥15 weeks will be assigned if the follow-up disease assessment has met the SD criteria at least once after the date of randomization at a minimum of 14 weeks (98 days) considering a one-week visit window. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted.
| Percentage of participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Disease Control Rate (DCR) Per RECIST v1.1 in mITT Population | 32.7 (20.3 to 47.1) | 36.4 (23.8 to 50.4) |
DCR per RECIST v1.1 based upon investigator assessment, was defined as the percentage of participants with a best overall response of CR or PR at any time plus stable disease (SD) meeting the minimum time of 15 weeks. A status of SD≥15 weeks will be assigned if the follow-up disease assessment has met the SD criteria at least once after the date of randomization at a minimum of 14 weeks (98 days) considering a one-week visit window. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
| Percentage of participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| DCR Per RECIST v1.1 in PD-L1 CPS ≥1 Population | 30.6 (18.3 to 45.4) | 34.6 (22.0 to 49.1) |
DoR per RECIST v1.1 is defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. Kaplan-Meier estimate for the median DoR is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.
| Months | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Duration of Response (DoR) Per RECIST v1.1 in mITT Population | NA (NA to NA) | 2.8 (1.2 to 2.8) |
DoR per RECIST v1.1 is defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. Kaplan-Meier estimate for the median DoR is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
| Months | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| DoR Per RECIST v1.1 in PD-L1 CPS ≥1 Population | NA (NA to NA) | 2.8 (1.4 to 2.8) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention
| Participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Number of Participants With Adverse Events (AEs) in Safety Population | 51 | 65 |
SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and other situations according to medical or scientific judgement.
| Participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) in Safety Population | 23 | 32 |
AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs).
| Participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Number of Participants With Adverse Events of Special Interest (AESI) in Safety Population | 29 | 43 |
Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
| Participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Number of Participants With AEs in Programmed Death Ligand-1 (PD-L1) Combined Positive Score (CPS ≥1) Population | 48 | 62 |
SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and other situations according to medical or scientific judgement. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
| Participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Number of Participants With SAEs in PD-L1 CPS ≥1 Population | 21 | 32 |
AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
| Participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Number of Participants With AESIs in PD-L1 CPS ≥1 Population | 27 | 40 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity for each AE was reported during the study and assigned a grade according to the NCI-CTCAE v5.0. from Grade 1 through Grade 5. Grade 1= mild toxicity; Grade 2 = moderate toxicity; Grade 3 = severe toxicity; Grade 4 = life-threatening or disabling toxicity, Grade 5 = death related to toxicity.
| Participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Grade 1 | 1 | 3 |
| Grade 2 | 17 | 15 |
| Grade 3 | 23 | 34 |
| Grade 4 | 4 | 10 |
| Grade 5 | 6 | 3 |
A SAE was defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. Severity for each SAE was reported during the study and assigned a grade according to the NCI-CTCAE v5.0. from Grade 1 through Grade 5. Grade 1= mild toxicity; Grade 2 = moderate toxicity; Grade 3 = severe toxicity; Grade 4 = life-threatening or disabling toxicity, Grade 5 = death related to toxicity. Data of participants experiencing SAEs of Grade \>= 3 has been presented.
| Participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Severity of SAEs in Safety Population | 17 | 26 |
AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). Severity of each AESI was reported during the study and was assigned a grade according to the NCI-CTCAE. AESIs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE. Data of participants experiencing AESIs of Grade \>= 3 have been presented.
| Participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Severity of AESIs in Safety Population | 5 | 4 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity for each AE was reported during the study and assigned a grade according to the NCI-CTCAE v5.0. from Grade 1 through Grade 5. Grade 1= mild toxicity; Grade 2 = moderate toxicity; Grade 3 = severe toxicity; Grade 4 = life-threatening or disabling toxicity, Grade 5 = death related to toxicity. Data of participants experiencing AEs of Grade \>= 3 have been presented. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
| Participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Severity of AEs in PD-L1 CPS ≥1 Population | 30 | 45 |
A SAE was defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. Severity for each SAE was reported during the study and assigned a grade according to the NCI-CTCAE v5.0. from Grade 1 through Grade 5. Grade 1= mild toxicity; Grade 2 = moderate toxicity; Grade 3 = severe toxicity; Grade 4 = life-threatening or disabling toxicity, Grade 5 = death related to toxicity. Data of participants that experienced SAEs of Grade \>= 3 have been presented. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
| Participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Severity of SAEs in PD-L1 CPS ≥1 Population | 15 | 26 |
AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). Severity of each AESI was reported during the study and was assigned a grade according to the NCI-CTCAE. AESIs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE. Data of participants that experienced AESIs of Grade \>= 3 have been presented.
| Participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Severity of AESI in PD-L1 CPS ≥1 Population | 5 | 4 |
Number of participants with dose modifications (including dose interruptions, dose delays, dose reductions and treatment discontinuations) were reported by each interventional component.
| Participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Dose interruption per component - feladilimab | 0 | NA |
| Dose interruption per component - placebo | NA | 0 |
| Dose interruption per component - pembrolizumab | 0 | 0 |
| Dose interruption per component - carboplatin/cisplatin | 1 | 1 |
| Dose interruption per component - fuorouracil | 0 | 7 |
| Dose delays per component - feladilimab | 13 | NA |
| Dose delays per component - placebo | NA | 12 |
| Dose delays per component - pembrolizumab | 13 | 13 |
| Dose delays per component - cisplatin/carboplatin | 12 | 9 |
| Dose delays per component - fluorouracil | 9 | 10 |
| Dose Reduction per component - feladilimab | NA | NA |
| Dose Reduction per component - placebo | NA | NA |
| Dose Reduction per component - pembrolizumab | NA | NA |
| Dose Reduction per component - carboplatin/cisplatin | 12 | 19 |
| Dose Reduction per component - fluorouracil | 18 | 21 |
| Treatment discontinuation per component - feladilimab/placebo | 50 | 56 |
| Treatment discontinuation per component - pembrolizumab | 10 | 15 |
| Treatment discontinuation per component - carboplatin/cisplatin | 16 | 18 |
| Treatment discontinuation per component - fluorouracil | 13 | 18 |
Number of participants with dose modifications (including dose interruptions, dose delays, dose reductions and treatment discontinuations) were reported by each interventional component. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.
| Participants | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Dose Interruptions per component- feladilimab | 0 | NA |
| Dose Interruptions per component- placebo | NA | 0 |
| Dose Interruptions per component- pembrolizumab | 0 | 0 |
| Dose Interruptions per component- carboplatin/cisplatin | 1 | 1 |
| Dose Interruptions per component- fluorouracil | 0 | 7 |
| Dose Delays per component - feladilimab | 12 | NA |
| Dose Delays per component - placebo | NA | 11 |
| Dose Delays per component - pembrolizumab | 2 | 12 |
| Dose Delays per component - carboplatin/cisplatin | 11 | 9 |
| Dose Delays per component - fluorouracil | 8 | 9 |
| Dose Reductions per component - feladilimab | NA | NA |
| Dose Reductions per component - placebo | NA | NA |
| Dose Reductions per component - pembrolizumab | NA | NA |
| Dose Reductions per component - carboplatin/cisplatin | 11 | 16 |
| Dose Reductions per component - fluorouracil | 16 | 19 |
| Treatment Discontinuations per component - feladilimab/placebo | 47 | 53 |
| Treatment Discontinuations per component - pembrolizumab | 10 | 14 |
| Treatment Discontinuations per component - carboplatin/cisplatin | 13 | 16 |
| Treatment Discontinuations per component - fluorouracil | 15 | 16 |
TTD in pain is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the European Organization for Research and Treatment of Cancer Item Library(EORTC IL51) Questionnaire pain domain, i.e. an increase from baseline of at least 8.33 observed at all subsequent non-missing visits. The EORTC Quality of Life Questionnaire 35-Item Head and Neck Module (QLQ-H\&N35) is a head and neck specific module with multi-item scales. The mouth pain, swallowing, speech problems, opening mouth, coughing, feeding tube, and trouble with social eating domains were administered and referred to as the EORTC IL51. The questionnaire scores for each scale and single-item measure are averaged and transformed linearly to present a score ranging from 0-100. A high score represents a high/healthy level of functioning. Kaplan-Meier estimate for the median TTD is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.
| Months | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| Time to Deterioration (TTD) in Pain in mITT Population | 4.4 (2.1 to 4.4) | 2.8 (1.4 to NA) |
TTD in pain is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the EORTC IL51 pain domain, i.e. an increase from baseline of at least 8.33 observed at all subsequent non-missing visits. The EORTC QLQ-H\&N35 is a head and neck specific module with multi-item scales. The mouth pain, swallowing, speech problems, opening mouth, coughing, feeding tube, and trouble with social eating domains were administered and referred to as the EORTC IL51. The questionnaire scores for each scale and single-item measure are averaged and transformed linearly to present a score ranging from 0-100. A high score represents a high/healthy level of functioning. Kaplan-Meier estimate for the median TTD is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells to the total number of viable tumor cells.
| Months | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| TTD in Pain in PD-L1 CPS ≥1 Population | 3.4 (1.3 to 4.4) | 2.8 (1.4 to NA) |
TTD in physical function (PF) is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the PF T-score, i.e. a decrease from baseline of at least 2.4 observed at all subsequent non-missing visits, as measured by the Patient-Reported Outcomes Measurement Information System - Physical Function (PROMIS PF 8c).The PROMIS PF 8c is an 8-item fixed length short form derived from the PROMIS Physical Function item bank. It includes a 5-point scale with three sets of response options. Scores on the PROMIS PF 8c are reported on a T score metric (mean = 50 and SD = 10), with higher scores reflecting better physical functioning.
| Months | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| TTD in Physical Function in mITT Population | 2.8 (1.4 to NA) | 4.3 (2.1 to 5.6) |
TTD in PF is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the PF T-score, i.e. a decrease from baseline of at least 2.4 observed at all subsequent non-missing visits, as measured by the PROMIS PF 8c.The PROMIS PF 8c is an 8-item fixed length short form derived from the PROMIS Physical Function item bank. It includes a 5-point scale with three sets of response options. Scores on the PROMIS PF 8c are reported on a T score metric (mean = 50 and SD = 10), with higher scores reflecting better physical functioning. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells
| Months | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| TTD in Physical Function in PD-L1 CPS ≥1 Population | 4.8 (2.1 to NA) | 4.3 (2.1 to 5.6) |
Collected over All cause mortality, non-SAEs and SAEs were collected from Day 1 to up to approximately 37.2 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | 33/51 (64.7%) | 23/51 (45.1%) | 50/51 (98%) |
| Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy | 39/65 (60%) | 32/65 (49.2%) | 63/65 (96.9%) |
| Event | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| PneumoniaInfections and infestations | 2/51 | 5/65 |
| Pneumonia aspirationInfections and infestations | 1/51 | 3/65 |
| PyrexiaGeneral disorders | 2/51 | 2/65 |
| COVID-19Infections and infestations | 2/51 | 1/65 |
| Acute kidney injuryRenal and urinary disorders | 2/51 | 1/65 |
| AnaemiaBlood and lymphatic system disorders | 1/51 | 2/65 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/51 | 2/65 |
| Acute myocardial infarctionCardiac disorders | 0/51 | 2/65 |
| DiarrhoeaGastrointestinal disorders | 1/51 | 2/65 |
| NauseaGastrointestinal disorders | 1/51 | 2/65 |
| Event | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 27/51 | 30/65 |
| NauseaGastrointestinal disorders | 22/51 | 32/65 |
| FatigueGeneral disorders | 17/51 | 24/65 |
| NeutropeniaBlood and lymphatic system disorders | 9/51 | 21/65 |
| DiarrhoeaGastrointestinal disorders | 10/51 | 21/65 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/51 | 17/65 |
| ConstipationGastrointestinal disorders | 13/51 | 16/65 |
| StomatitisGastrointestinal disorders | 12/51 | 16/65 |
| Mucosal inflammationGeneral disorders | 6/51 | 16/65 |
| VomitingGastrointestinal disorders | 8/51 | 13/65 |
| Age, Customized(Participants) | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy | Total |
|---|---|---|---|
| 18-64 years | 37 | 40 | 77 |
| >=65-84 years | 20 | 20 | 40 |
| Sex: Female, Male(Participants) | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy | Total |
|---|---|---|---|
| Female | 10 | 14 | 24 |
| Male | 47 | 46 | 93 |
| Race/Ethnicity, Customized(Participants) | Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy | Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy | Total |
|---|---|---|---|
| Asian - Central/South Asian Heritage | 2 | 1 | 3 |
| Asian - East Asian Heritage | 5 | 7 | 12 |
| Asian - Japanese Heritage | 2 | 0 | 2 |
| Asian - South East Asian Heritage | 2 | 1 | 3 |
| Black or African American | 1 | 0 | 1 |
| Missing | 2 | 1 | 3 |
| White - White/Caucasian/European Heritage | 43 | 50 | 93 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Aug 2020 to primary completion in Apr 2021, 8 months.
Results were first posted in May 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Feladilimab
Squamous Cell Carcinoma of Head and Neck →